ARCHIVES

NCI To require Prompt Publication Of Data Affected By Falsification In Future Grants

This article is from The Cancer Letter archive.

Vol. 20 No. 14 | April 8, 1994

Download PDF Visit The Full Archive

Related Articles

FDA Advisors Oppose Group’s Tamoxifen Trial, But Okay The Idea

July 6, 1990

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

January 27, 2012

NCI-Approved Clinical Trials

September 28, 2001

In Brief: John Kovach Succeeds Moertel As Mayo CC Head; DEA Deputy Appointed; New NCAB Member Named

February 7, 1986

NCI Oks Expanded Breast Cancer Low Fat Prevention Trial, Plans To End Stage 2 Adjuvant Low Fat Study

January 31, 1986

Senate Votes To Invalidate Task Force Guideline

December 4, 2009